The estimated Net Worth of Cabot Brown is at least 1.25 百万$ dollars as of 18 March 2021. Mr. Brown owns over 4,020 units of GW Pharmaceuticals stock worth over 504$ and over the last 6 years he sold GWPH stock worth over 878,003$. In addition, he makes 374,844$ as Non-Executive Independent Director at GW Pharmaceuticals.
Sign up
Mr. Brown GWPH stock SEC Form 4 insiders trading
Cabot has made over 7 trades of the GW Pharmaceuticals stock since 2019, according to the Form 4 filled with the SEC. Most recently he sold 4,020 units of GWPH stock worth 72,159$ on 18 March 2021.
The largest trade he's ever made was selling 52,104 units of GW Pharmaceuticals stock on 1 March 2019 worth over 749,256$. On average, Cabot trades about 7,314 units every 80 days since 2019. As of 18 March 2021 he still owns at least 7,200 units of GW Pharmaceuticals stock.
You can see the complete history of Mr. Brown stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Cabot Brown biography
Cabot Brown serves as Non-Executive Independent Director of the Company. Mr. Brown has decades of business, operational and board of director experience with a broad range of companies. Mr. Brown is the founder and chief executive officer of Carabiner LLC, a strategic and financial advisory firm based in San Francisco that specializes in healthcare and education. Previously, Mr. Brown served as a Managing Director and Head of the Healthcare Group at GCA Savvian, an international financial advisory firm, from 2011 to 2012. Before joining GCA Savvian, Mr. Brown worked for 10 years at Seven Hills Group, an investment banking group he co-founded where he also directed the firm’s healthcare activities. He also was Managing Director of Brown, McMillan & Co, an investment firm he co-founded that sponsored buy-outs and venture capital investments. From 1987 until 1995, Mr. Brown worked at Volpe, Welty & Company, a boutique investment bank where he co-founded and ran the healthcare practice and served as a member of its Executive Committee. Mr. Brown holds an MBA from Harvard Business School with high distinction as a George F. Baker Scholar and an AB cum laude in Government from Harvard College.
What is the salary of Cabot Brown?
As the Non-Executive Independent Director of GW Pharmaceuticals, the total compensation of Cabot Brown at GW Pharmaceuticals is 374,844$. There are 7 executives at GW Pharmaceuticals getting paid more, with Justin Gover having the highest compensation of 7,864,300$.
How old is Cabot Brown?
Cabot Brown is 58, he's been the Non-Executive Independent Director of GW Pharmaceuticals since 2013. There are 5 older and 8 younger executives at GW Pharmaceuticals. The oldest executive at GW Pharmaceuticals is William Waldegrave, 73, who is the Non-Executive Independent Director.
What's Cabot Brown's mailing address?
Cabot's mailing address filed with the SEC is SOVEREIGN HOUSE, VISION PARK, HISTON, , CAMBRIDGE, X0, CB24 9BZ.
Insiders trading at GW Pharmaceuticals
Over the last 6 years, insiders at GW Pharmaceuticals have traded over 60,899,192$ worth of GW Pharmaceuticals stock and bought 7,200 units worth 48,960$ . The most active insiders traders include Geoffrey W Dr Guy、James Noble、Justin D. Gover. On average, GW Pharmaceuticals executives and independent directors trade stock every 10 days with the average trade being worth of 8,011$. The most recent stock trade was executed by Douglas B. Snyder on 6 April 2021, trading 8,400 units of GWPH stock currently worth 152,208$.
What does GW Pharmaceuticals's logo look like?
Complete history of Mr. Brown stock trades at GW Pharmaceuticals
GW Pharmaceuticals executives and stock owners
GW Pharmaceuticals executives and other stock owners filed with the SEC include:
-
Justin Gover,
Chief Executive Officer, Executive Director -
Geoffrey Guy,
Executive Chairman of the Board -
Volker Knappertz,
Chief Medical Officer -
Douglas Snyder,
Chief Legal Officer -
Scott Giacobello,
Chief Financial Officer -
Christopher Tovey,
Chief Operating Officer -
Adam George,
Managing Director - U.K., Company Secretary -
Cabot Brown,
Non-Executive Independent Director -
James Noble,
Non-Executive Independent Director -
Catherine Mackey,
Non-Executive Independent Director -
Alicia Secor,
Non-Executive Independent Director -
William Waldegrave,
Non-Executive Independent Director -
David Gryska,
Independent Director -
Stephen Schultz,
Vice President, Investor Relations -
Darren Cline,
Chief Commercial Officer - U.S. -
Thomas G Lynch,
Director -
Julian S Gangolli,
President, North America